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Melanoma is one of the most aggressive and drug-resistant cancers. Despite novel promising 24 
therapeutic strategies, the prognosis of metastatic melanoma patients remains poor and it is 25 
often associated with high relapse rates. Endophilin B1, also known as BIF-1, is a 26 
multifunctional protein involved in several biological processes such as autophagy and 27 
apoptosis. BIF-1 promotes apoptosis through binding to BAX and its translocation to the 28 
mitochondrial outer membrane. On the other hand, BIF-1 can interact with Beclin-1 through 29 
UVRAG to promote autophagy. Several reports suggest an ambiguous role of BIF-1 in cancer 30 
development and progression. For example, it has been demonstrated that the expression of 31 
BIF-1 is reduced in both primary and metastatic melanoma and that the reduction of BIF-1 32 
expression is associated with reduced overall survival of melanoma patients. Here we show 33 
that the expression of Beclin-1 and the active form of BAX are also reduced in melanoma 34 
patients. However, while we observed strong positive correlations between the expression of 35 
BIF-1 and Beclin-1 as well as between BIF-1 and BAX in benign nevi, these correlations were 36 
lost in primary and metastatic melanoma cells. These data indicate a dysfunctionality in the 37 
proximal molecular mechanisms which regulate the expression of BIF-1, Beclin-1 and BAX in 38 
primary and metastatic melanoma. 39 




Despite new promising therapeutic approaches, such as immunotherapy or targeted therapy, 42 
the prognosis of metastatic melanoma patients remains poor and is often associated with high 43 
tumor relapse rates. Unfortunately, prognostic factors that are currently used in clinics are not 44 
sufficient to clearly identify high-risk melanoma patients. BIF-1, also known as endophilin B1 45 
or BAX-interacting protein 1, is part of the endophilin family of proteins, which are 46 
cytoplasmic proteins involved in numerous biological processes, such as mitochondrial 47 
membrane dynamics, apoptosis, autophagy, synaptic vesicle retrieval as well as receptor 48 
tyrosine trafficking and signaling [1]. We have previously demonstrated that the expression of 49 
BIF-1 is reduced in primary and metastatic melanomas as compared to healthy tissues and that 50 
the reduced BIF-1 levels are associated with a less favorable clinical outcome [2].  51 
BIF-1 is mostly found in the cytosol and a fraction of the protein also resides on 52 
intracellular membranous compartments, including the Golgi complex and mitochondria [3-6], 53 
where it was shown to be required for the maintenance of mitochondrial morphology and  54 
function [2, 4]. Since its discovery as an interacting partner of BAX, several reports focused 55 
on its role in apoptosis. Moreover, depletion of BIF-1 expression in HeLa cells delays the 56 
conformational change of BAX and BAK, cytochrome c release, and caspase-3 activation 57 
induced by various intrinsic death signals [3, 6]. Besides being involved in BAX activation, it 58 
was also shown that BIF-1 forms a complex with Beclin-1 through UVRAG and positively 59 
modulates the formation of autophagosomes [7]. The involvement of BIF-1 in autophagy and 60 
apoptosis led to several investigations of the role of BIF-1 in cancer. Low expression of BIF-1 61 
was found, besides melanoma [2], in invasive urinary bladder and gallbladder cancers [8] as 62 
well as in colorectal adenocarcinoma [9]. In contrast, high expression was reported in 63 
hepatocellular carcinoma [10]. Moreover, loss of BIF-1 in melanoma cells led to increased 64 
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ATP production, metabolic acidification, and mitochondrial respiration which was associated 65 
with higher proliferation rates both in vitro and in vivo [2]. 66 
Because of the role of BIF-1 in apoptosis and autophagy, we decided to investigate the 67 
correlation between the expression of apoptotic or autophagic proteins and BIF-1 in benign 68 
nevi as compared to primary and metastatic melanoma tissues. We show that the expression of 69 
active form of BAX is reduced in metastatic melanoma patients. Additionally, we could 70 
demonstrate that the expression of an essential autophagic protein Beclin-1 is also reduced in 71 
metastatic melanoma patients as compared to benign nevi. Moreover, the positive correlation 72 
between BIF-1 and the active form of BAX, Beclin-1 or the autophagic marker LC3B was lost 73 
in primary and metastatic melanoma cells. These data suggest that the proximal events 74 
regulating the expression of BIF-1, Beclin-1 and BAX are dysregulated in primary and 75 
metastatic melanoma cells.  76 
 77 
  78 
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Materials and methods 79 
Study design and patients 80 
The Tissue Micro Array (TMA) was constructed by the Department of Pathology, Bern. The 81 
study was approved by the Ethics Committee of the Canton of Bern. This cohort study aimed 82 
at investigating the role of BIF-1, BAX, LC3B and Beclin-1 in the pathogenesis of cutaneous 83 
melanoma. TMA included archived tissue samples of consecutive 65 melanocytic nevi, 41 84 
primary and 30 metastatic melanomas obtained between the years 2003 and 2015 from patients 85 
at the Department of Dermatology, Inselspital, Bern, Switzerland.  86 
 87 
Immunohistochemistry 88 
IHC was performed as previously described [2, 11, 12]. Briefly, paraffin-embedded tissue 89 
sections were deparaffinized and rehydrated with graded ethanol dilutions which was followed 90 
by the antigen retrieval. Immunohistochemical staining was performed with the Dako REAL 91 
Detection System, using the Alkaline Phosphatase/RED kit, which also provided the secondary 92 
antibodies, according to the manufacturer’s instructions (Agilent Technologies, K5005). The 93 
following primary antibodies were used: monoclonal anti-endophilin B1/BIF-1 antibody 94 
(Novus Biologicals, NBP2-24733; 1:100), polyclonal rabbit anti-Beclin-1 antibody (Abgent, 95 
San Diego, CA, USA; 1:100), monoclonal anti–BAX (clone 6A7, Santa Cruz Biotechnology, 96 
Dallas, TX, USA; 1:100) and polyclonal rabbit anti-LC3B antibody (Abgent, 1:100). The 97 
intensity of staining was evaluated by QuPath software [2, 13] and is presented as the mean 98 
optical density (OD) or by Image Pro Plus software and presented as integrated optical density 99 




Statistical analysis 102 
Data were presented as means ± SD using the Prism Software v6 (GraphPad, La Jolla, CA, 103 
US). Significant values were represented according to the following convention: p ≥ 0.05ns, p 104 
≤ 0.05*, p ≤ 0.01**, p ≤ 0.001***, and p ≤ 0.0001****. The follow-up data on primary and 105 
metastatic melanoma patients were divided for analysis into two groups according to the 106 
median expression of active form of BAX or Beclin-1 in their tumors. The group with “High 107 
BAX or Beclin-1” included patients with BAX or Beclin-1 levels that were higher than the 108 
median value of the whole population.  The group with “Low BAX or Beclin-1” included 109 
patients with BAX or Beclin-1 levels that were lower than the median value of the whole 110 
population. Overall survival (OS) was defined as the time from random assignment to death 111 
from any cause. Disease-free survival (DFS) was defined as the time from random assignment 112 
to disease reoccurrence or progression.  It was analyzed with the log-rank test and plotted as 113 
Kaplan-Meier survival curves.  114 




Reduced active BAX expression in metastatic melanoma patients 117 
Our previous findings suggested that BIF-1 is a tumor suppressor in melanoma because it limits 118 
tumor growth by inhibiting mitochondrial functions. Several studies demonstrated that BIF-1 119 
enhances apoptosis through promoting the conformational changes of BAX and BAK and the 120 
translocation of BAX to the mitochondria [3, 6]. Apoptosis is a crucial cell death mechanism 121 
by which damaged or transformed cells, which could be potentially cancerous, are eliminated. 122 
We decided to first investigate the expression of the conformational active form of BAX across 123 
several stages of melanoma development using a custom made tissue microarray (TMA) [2]. 124 
TMA contained 64 benign nevi, 41 primary melanoma and 30 metastatic melanoma tissue 125 
samples. Immunohistochemistry analysis of the TMA revealed a step wise decrease in the 126 
expression of active BAX from benign nevi via primary melanoma to metastatic melanoma 127 
(Fig. 1a). The expression of active BAX was significantly decreased in metastatic melanoma 128 
(mean OD = 0.1116 ± 0.03897) as compared to benign nevi (mean OD = 0.1588 ± 0.05966).  129 
To our surprise, further stratification of patients according to their median BAX expression in 130 
groups with high (OD > 0.1344 for primary melanoma and OD > 0.1274 for metastatic 131 
melanomas) or low active BAX expression showed that the active form of BAX does not have 132 






Reduced Beclin-1 expression in metastatic melanoma patients 137 
In addition to apoptosis, BIF-1 has also been associated with autophagy. BIF-1 interact with 138 
Beclin-1 through binding to UVRAG and acts as a positive mediator of the class III PI(3) kinase 139 
and autophagy [7]. We next investigated the expression of Beclin-1 in benign nevi and 140 
melanoma patients. We observed a slight decrease in Beclin-1 expression in primary melanoma 141 
and a robust decrease of Beclin-1 expression in metastatic melanoma patients compared to 142 
benign nevi (Fig. 2a). Interestingly, stratification of patients according to their Beclin-1 median 143 
expression in groups with high (IOD > 9316.11 for primary melanoma and IOD > 808.272 for 144 
Fig. 1. Expression of BAX active monomeric form is reduced in metastatic melanomas  
compared with benign melanocytic nevi. a) Immunohistochemistry. Quantification of the  
BAX active monomeric form signal intensity. Intensity (mean optical density (OD)) values for  
individual patients are presented. The red lines represent the mean of all values. Statistical  
differences were analyzed by one-way ANOVA using a Kruskal-Wallis test and Dunn’s post  
hoc test (left panel). Representative images of 65 benign nevi as well as 41 primary and 30  
metastatic melanomas are shown (right panel). b) The same follow-up patients were divided  
into two groups (“high” and “low”) on the basis of the median expression of BAX in their  
tumors. Kaplan-Meier curves for overall and disease-free survival are shown.   
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metastatic melanomas) or low Beclin-1 expression revealed that Beclin-1 expression does not 145 
influence the OS or DFS of melanoma patients (Fig. 2b).   146 
 147 
Fig. 2. Expression of Beclin-1 is reduced in metastatic melanomas compared with benign 148 
melanocytic nevi. a) Immunohistochemistry. Quantification of the Beclin-1 signal intensity. 149 
Intensity (integrated optical density (IOD)) values for individual patients are presented. The 150 
red lines represent the mean of all values. Statistical differences were analyzed by one-way 151 
ANOVA using a Kruskal-Wallis test and Dunn’s post hoc test (left panel). Representative 152 
images of 65 benign nevi as well as 41 primary and 30 metastatic melanomas are shown (right 153 
panel). b) The same follow-up patients were divided into two groups (“high” and “low”) on the 154 
basis of the median expression of Beclin-1in their tumors. Kaplan-Meier curves for overall and 155 
disease-free survival are shown. 156 
 157 
The correlations of BIF-1 with active BAX, Beclin-1 or LC3B expression are lost in 158 
primary and metastatic melanomas 159 
Since BIF-1 has been implicated in autophagy and apoptosis and since those processes are 160 
crucial in preventing tumor development or progression, we decided to investigate whether 161 
10 
 
proteins involved in autophagy or apoptosis have a similar expression pattern as BIF-1 in 162 
benign nevi and melanoma patients.  For this purpose, we analysed the correlation between 163 
BIF-1 and the active form of BAX and Beclin-1. We observed a strong correlation between 164 
BIF-1 and the active form of BAX in benign nevi (Fig. 3a), suggesting a similar or the same 165 
mechanism regulating these two proteins in melanocytes. Interestingly, the correlation between 166 
BIF-1 and the active form of BAX was lost in primary and metastatic melanoma tissues (Fig. 167 
3b and 3c).  168 
 169 
Fig. 3. BIF-1 positively correlates with BAX active monomeric form in benign nevi but 170 
not in primary or metastatic melanoma samples. (a-c) The scatter plot shows the correlation 171 
between the mean OD values of BAX active monomeric form with BIF-1 in benign nevi (a), 172 
primary melanoma (b) and metastatic melanoma (c) samples. The reported r and p -values show 173 
the Pearson correlation.  174 
 175 
In addition, to the interaction with BAX, BIF-1 also forms a complex with Beclin-1 176 
through UVRAG, influencing the induction of autophagy [7]. Beclin-1 is a central regulator of 177 
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autophagy and acts in the initiation phase of autophagy by forming the isolation membrane that 178 
engulfs the cytoplasmic material [14]. Therefore, we also investigated the expression of Beclin-179 
1 and observed a strong correlation between active BAX and Beclin-1 in benign nevi (Fig. 4a) 180 
and loss of this correlation in primary and metastatic melanoma tissue (Fig. 4b and 4c).  181 
 182 
Fig. 4. BIF-1 positively correlates with Beclin-1 in benign nevi but not in primary or 183 
metastatic melanoma samples. (a-c) The scatter plot shows the correlation between the IOD 184 
values of Beclin-1 with mean OD values of BIF-1 in benign nevi (a), primary melanoma (b) 185 
and metastatic melanoma (c) samples. The reported r and p -values show the Pearson 186 
correlation. 187 
 188 
Since BIF-1 is a positive regulator of autophagy, we also investigated the correlation 189 
between the expression of BIF-1 and a commonly used autophagic marker LC3B. Upon 190 
cleavage and lipidation with phosphatidylethanolamine (PE), LC3 is found on the inner and 191 
outer autophagosomal membrane [15]. In agreement with the role of BIF-1 in autophagy, we 192 
observed a strong positive correlation between the levels of BIF-1 and LC3B in benign nevi 193 
(Fig.5a) that was lost in primary and metastatic melanoma tissues (Fig. 5b and 5c). These 194 
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findings indicate that the proximal regulation of the expression of BIF-1, Beclin-1 and BAX is 195 
dysregulated in primary and metastatic melanoma cells. 196 
 197 
Fig. 5. BIF-1 positively correlates with LC3B in benign nevi but not in primary or 198 
metastatic melanoma samples. (a-c) The scatter plot shows the correlation between the IOD 199 
values of LC3B with mean OD values of BIF-1 in benign nevi (a), primary melanoma (b) and 200 
metastatic melanoma (c) samples. The reported r and p -values show the Pearson correlation. 201 
 202 
Discussion 203 
BIF-1 has been associated with several biological processes, in particular apoptosis, during 204 
which it interacts with BAX and promotes its conformational changes during cell death [3, 6]. 205 
We therefore wanted to investigate the BIF-1-BAX axis in our cohort of melanoma patients. 206 
Using a conformation-specific BAX antibody recognizing an activated form of BAX, we found 207 
a consistent reduction in active BAX associated with lower BIF-1 levels in metastatic 208 
melanoma tissue sections as compared to benign nevi. Moreover, we observed a positive 209 
correlation between the expression of BIF-1 and active BAX in nevi in which the mitochondrial 210 
apoptotic pathway is active [16]. In contrast, this correlation did no longer exist in melanoma 211 
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cells, suggesting that the apoptosis resistance, frequently arising in melanoma tumors, could 212 
be, at least partially, explained by downregulation of BIF-1.  213 
Autophagy and apoptosis are both crucial cellular processes in determining the cellular 214 
fate and have a high impact on the development and progression of neoplasms [17]. Apoptosis 215 
is the most common physiological form of cell death in the absence of inflammation [18]. The 216 
intrinsic apoptotic pathway is regulated by the BCL-2 family of proteins and involves 217 
mitochondrial outer membrane permabilization (MOMP) which leads to the release of the pro-218 
apoptotic factors such as cytochrome c and SMAC/DIABLO from the mitochondria to the 219 
cytosol. MOMP is followed by the activation of the caspase cascade which leads to cell death 220 
[19]. In healthy cells, the core pro-apoptotic regulators BAX and BAK shuttle between the 221 
outer mitochondrial membrane (OMM) and the cytosol [20, 21]. Under apoptotic conditions, 222 
BAX and BAK are activated and undergo dimerization and assemble at the OMM where they 223 
form multimeric pores [21]. The balance of interaction between pro-apoptotic and anti-224 
apoptotic proteins, such as BCL-2 or BCL-XL, ensures appropriate apoptotic regulation in 225 
response to cellular stresses and other cell death triggering factors [19].  226 
Loss of BAX expression has been reported as a negative prognostic marker in several 227 
cancers, such as breast, ovarian, pancreatic, and esophageal cancer [22-25]. Additionally, 228 
Fecker et al. have previously shown that loss of BAX in primary superficial-spreading 229 
melanomas was associated with tumor progression and reduced survival rates [26]. Moreover, 230 
downregulation of BAX in stage IIa melanomas was associated with an increased risk of 231 
development of metastasis and poor prognosis [27].  232 
Interestingly, Beclin-1 has been identified as an interaction partner of BCL-2, BCL-XL 233 
and MCL-1. Those interactions may regulate the crosstalk between apoptotic and autophagic 234 
signalling pathways [17]. Besides being involved in BAX activation, BIF-1 also forms a 235 
complex with Beclin-1 through UVRAG and positively regulates the formation of 236 
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autophagosomes [7]. Here we show that the expression of Beclin-1 is reduced in melanoma 237 
tissues as compared to benign nevi. Moreover, besides the positive correlation between BIF-1 238 
and BAX, we also observed a strong correlation between the expression of BIF-1 and Beclin-239 
1 in melanocytes that was lost in primary and metastatic melanoma tissues. Furthermore, we 240 
observed the same correlation pattern between BIF-1 and the autophagic marker LC3B.  241 
Several reports have pointed to a tumor suppressing role of autophagy. Beclin-1 has 242 
been described as a tumor suppressor gene because it was found to be monoallelically deleted 243 
in 40% to 75% of human breast, ovarian, and prostate tumors [28]. Moreover, allelic loss of 244 
Beclin-1 in mice led to high occurrence of tumors such as B cell lymphoma, hepatocellular 245 
carcinoma and lung adenocarcinoma [29]. A link between the role of Beclin-1 in melanoma 246 
was described in recently published work demonstrating that decreased Beclin-1 expression 247 
correlates with invasiveness and a decrease in 5-year survival after surgery [30]. 248 
In summary, our findings indicate that the proximal regulation responsible for a 249 
coordinated expression of BIF-1, Beclin-1 and BAX in melanocytes appears to be lost in 250 
primary and metastatic melanoma cells. It is likely that the reduced expression of BIF-1, 251 
Beclin-1 and BAX and its anticipated dysfunctional proximal regulatory mechanism 252 
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Figure legends 382 
Fig. 1. Expression of BAX active monomeric form is reduced in metastatic melanomas 383 
compared with benign melanocytic nevi. a) Immunohistochemistry. Quantification of the 384 
BAX active monomeric form signal intensity. Intensity (mean optical density (OD)) values for 385 
individual patients are presented. The red lines represent the mean of all values. Statistical 386 
differences were analyzed by one-way ANOVA using a Kruskal-Wallis test and Dunn’s post 387 
hoc test (left panel). Representative images of 65 benign nevi as well as 41 primary and 30 388 
metastatic melanomas are shown (right panel). b) The same follow-up patients were divided 389 
into two groups (“high” and “low”) on the basis of the median expression of BAX in their 390 
tumors. Kaplan-Meier curves for overall and disease-free survival are shown.  391 
 392 
Fig. 2. Expression of Beclin-1 is reduced in metastatic melanomas compared with benign 393 
melanocytic nevi. a) Immunohistochemistry. Quantification of the Beclin-1 signal intensity. 394 
Intensity (integrated optical density (IOD)) values for individual patients are presented. The 395 
red lines represent the mean of all values. Statistical differences were analyzed by one-way 396 
ANOVA using a Kruskal-Wallis test and Dunn’s post hoc test (left panel). Representative 397 
images of 65 benign nevi as well as 41 primary and 30 metastatic melanomas are shown (right 398 
panel). b) The same follow-up patients were divided into two groups (“high” and “low”) on the 399 
basis of the median expression of Beclin-1in their tumors. Kaplan-Meier curves for overall and 400 
disease-free survival are shown. 401 
 402 
Fig. 3. BIF-1 positively correlates with BAX active monomeric form in benign nevi but 403 
not in primary or metastatic melanoma samples. (a-c) The scatter plot shows the correlation 404 
between the mean OD values of BAX active monomeric form with BIF-1 in benign nevi (a), 405 
primary melanoma (b) and metastatic melanoma (c) samples. The reported r and p -values show 406 
the Pearson correlation. 407 
 408 
Fig. 4. BIF-1 positively correlates with Beclin-1 in benign nevi but not in primary or 409 
metastatic melanoma samples. (a-c) The scatter plot shows the correlation between the IOD 410 
values of Beclin-1 with mean OD values of BIF-1 in benign nevi (a), primary melanoma (b) 411 
and metastatic melanoma (c) samples. The reported r and p -values show the Pearson 412 
correlation. 413 
 414 
Fig. 5. BIF-1 positively correlates with LC3B in benign nevi but not in primary or 415 
metastatic melanoma samples. (a-c) The scatter plot shows the correlation between the IOD 416 
values of LC3B with mean OD values of BIF-1 in benign nevi (a), primary melanoma (b) and 417 
metastatic melanoma (c) samples. The reported r and p -values show the Pearson correlation. 418 
 419 
